secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2026-06-04T20:15:32+00:00
Accession:  0001213900-26-065294
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Therapeutics stockholders elect directors, ratify auditor, approve say-on-pay at annual meeting
--------------------------------------------------------------------------------

- Lawrence Klein (43.9M votes for) and Chris Martin (43.9M for) elected as Class II directors; 1.3M broker non-votes.
- Ratification of PricewaterhouseCoopers as auditor for FY2026 passed: 45.2M for, 39,637 against, 3,432 abstain.
- Non-binding advisory vote on named executive officer compensation approved: 43.0M for, 875,114 against, 73,091 abstain; 1.3M broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390026065294/0001213900-26-065294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390026065294/ea0293648-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-065294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer